Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has patented new tricyclic compounds acting as serine/threonine-protein kinase ATR inhibitors and thus reported to be useful for the treatment of colon ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) released its third-quarter financial results for 2024, reporting key ...

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for ...

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), ...

Active enrollment is also ongoing in the Phase 1/2a ABOYA-119 study evaluating ATRN-119, our first-in-class macrocyclic ATR inhibitor. To optimize dosing and scheduling we added a twice-daily ...

Dr. Martin Højgaard of Rigshospitalet, Denmark presented this data in a poster titled, “Individualized schedule improves rates and severity of anaemia in patients treated with lunresertib, a PKMYT1 ...

The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR ...